Responses
Section 6: Education and research
6ER-024 Comparison of reductions in monthly migraine days between new small molecule cgrp receptor antagonists (gepants) and monoclonal antibodies targeting cgrp/cgrp receptor
Compose a Response to This Article
Other responses
No responses have been published for this article.